Predicting recurrence of non-small cell lung cancer based on mean computed tomography value.
Adult
Aged
Aged, 80 and over
Carcinoma
/ diagnostic imaging
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Female
Follow-Up Studies
Humans
Logistic Models
Lung
/ diagnostic imaging
Lung Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnostic imaging
Neoplasm Staging
Pneumonectomy
Predictive Value of Tests
ROC Curve
Retrospective Studies
Risk Assessment
Tomography, X-Ray Computed
Treatment Outcome
Ground-glass opacity
Mean- computed tomography value
Recurrence free survival
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
12 May 2021
12 May 2021
Historique:
received:
13
10
2020
accepted:
05
04
2021
entrez:
13
5
2021
pubmed:
14
5
2021
medline:
1
7
2021
Statut:
epublish
Résumé
The aim of this study was to assess the ability of using mean computed tomography (mCT) values to predict non-small cell lung cancer (NSCLC) tumor recurrence. A retrospective study was conducted on 494 patients with stage IA NSCLC. Receiver operating characteristics analysis was used to assess the ability to use mCT value, C/T ratio, tumor size, and SUV to predict tumor recurrence. Multiple logistic regression analyses were performed to determine the independent variables for the prediction of tumor recurrence. The m-CT values were - 213.7 ± 10.2 Hounsfield Units (HU) for the recurrence group and - 594.1 ± 11.6 HU for the non-recurrence group (p < 0.0001). Recurrence occurred in 45 patients (9.1%). The tumor recurrence group was strongly associated with a high CT attenuation value, high C/T ratio, large solid tumor size, and SUV. The diagnostic value of mCT value was more accurate than the C/T ratio, excluding the pure ground-glass opacity and pure solid (0 < C/T ratio < 100) groups. The SUV and mCT are independent predictive factors of tumor recurrence. The evaluation of mCT values was useful for predicting recurrence after the limited resection of small-sized NSCLC, and may potentially contribute to the selection of suitable treatment strategies.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to assess the ability of using mean computed tomography (mCT) values to predict non-small cell lung cancer (NSCLC) tumor recurrence.
METHODS
METHODS
A retrospective study was conducted on 494 patients with stage IA NSCLC. Receiver operating characteristics analysis was used to assess the ability to use mCT value, C/T ratio, tumor size, and SUV to predict tumor recurrence. Multiple logistic regression analyses were performed to determine the independent variables for the prediction of tumor recurrence.
RESULTS
RESULTS
The m-CT values were - 213.7 ± 10.2 Hounsfield Units (HU) for the recurrence group and - 594.1 ± 11.6 HU for the non-recurrence group (p < 0.0001). Recurrence occurred in 45 patients (9.1%). The tumor recurrence group was strongly associated with a high CT attenuation value, high C/T ratio, large solid tumor size, and SUV. The diagnostic value of mCT value was more accurate than the C/T ratio, excluding the pure ground-glass opacity and pure solid (0 < C/T ratio < 100) groups. The SUV and mCT are independent predictive factors of tumor recurrence.
CONCLUSIONS
CONCLUSIONS
The evaluation of mCT values was useful for predicting recurrence after the limited resection of small-sized NSCLC, and may potentially contribute to the selection of suitable treatment strategies.
Identifiants
pubmed: 33980268
doi: 10.1186/s13019-021-01476-0
pii: 10.1186/s13019-021-01476-0
pmc: PMC8117299
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Références
J Thorac Oncol. 2014 Apr;9(4):469-72
pubmed: 24736068
Ann Thorac Surg. 2017 Jul;104(1):261-266
pubmed: 28410633
Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6
pubmed: 15145016
Br J Radiol. 2009 Jul;82(979):532-40
pubmed: 19124564
Lancet. 1998 Apr 25;351(9111):1242-5
pubmed: 9643744
J Clin Oncol. 2002 Feb 15;20(4):911-20
pubmed: 11844811
Cancer. 1994 Feb 15;73(4):1177-83
pubmed: 7906193
AJR Am J Roentgenol. 2001 Jun;176(6):1399-407
pubmed: 11373200
Lung Cancer. 2001 Jul;33(1):17-25
pubmed: 11429192
J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12
pubmed: 170482
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
pubmed: 7677489
Chest. 2007 Jul;132(1):170-7
pubmed: 17505030
Gen Thorac Cardiovasc Surg. 2019 Oct;67(10):861-866
pubmed: 30820912
Chest. 2007 Sep;132(3):984-90
pubmed: 17573486
AJR Am J Roentgenol. 2014 Mar;202(3):W224-33
pubmed: 24555618
J Thorac Cardiovasc Surg. 1994 Oct;108(4):684-6
pubmed: 7934103
Ann Thorac Surg. 2006 Feb;81(2):413-9
pubmed: 16427823
J Thorac Cardiovasc Surg. 2013 Jul;146(1):24-30
pubmed: 23398645
Radiographics. 2007 Mar-Apr;27(2):391-408
pubmed: 17374860
Ann Thorac Surg. 2003 Sep;76(3):867-71
pubmed: 12963218
Ann Thorac Surg. 1996 Nov;62(5):1489-93
pubmed: 8893589